We are live on ! Find out more
SIOX

Sio Gene Therapies Inc. Common Stock

Delisted

SIOX was delisted on the 22nd of March, 2023.

39 hedge funds and large institutions have $19.1M invested in Sio Gene Therapies Inc. Common Stock in 2019 Q2 according to their latest regulatory filings, with 5 funds opening new positions, 12 increasing their positions, 17 reducing their positions, and 23 closing their positions.

New
Increased
Maintained
Reduced
Closed

19% more call options, than puts

Call options by funds: $3.86M | Put options by funds: $3.25M

29% less repeat investments, than reductions

Existing positions increased: 12 | Existing positions reduced: 17

32% less funds holding

Funds holding: 5739 (-18)

60% less capital invested

Capital invested by funds: $48.4M → $19.1M (-$29.3M)

78% less first-time investments, than exits

New positions opened: 5 | Existing positions closed: 23

100% less funds holding in top 10

Funds holding in top 10: 10 (-1)

Holders
39
Holders Change
-18
Holders Change %
-31.58%
% of All Funds
0.85%
Holding in Top 10
Holding in Top 10 Change
-1
Holding in Top 10 Change %
-100%
% of All Funds
New
5
Increased
12
Reduced
17
Closed
23
Calls
$3.86M
Puts
$3.25M
Net Calls
+$608K
Net Calls Change
+$675K

SIOX Hedge Fund Activity: Q2 2019 in Review

39 of the 4,604 institutional investors tracked by Wall St. Rank reported a position in Sio Gene Therapies Inc. Common Stock (SIOX) for Q2 2019, worth a combined $19.1M — down 60% from $48.4M a quarter earlier.

Sellers outnumbered buyers: 23 funds closed out of SIOX and 5 opened new positions — a net loss of 18 holders — while 17 trimmed existing stakes and 12 added.

The largest buyer was Citadel Advisors, adding an estimated $3.16M. The largest seller was CVI Holdings, exiting entirely with an estimated $8.16M sold.

  • 39 institutional investors held Sio Gene Therapies Inc. Common Stock (SIOX) as of Q2 2019, down from 57 in Q1 2019.
  • Funds reported $19.1M of Sio Gene Therapies Inc. Common Stock stock for Q2 2019, down 60% quarter-over-quarter.
  • 5 funds opened new Sio Gene Therapies Inc. Common Stock positions in Q2 2019 and 23 closed out, a net change of -18 holders.
  • The largest Sio Gene Therapies Inc. Common Stock buyer in Q2 2019 was Citadel Advisors, an estimated $3.16M added.
  • The largest Sio Gene Therapies Inc. Common Stock seller in Q2 2019 was CVI Holdings, an estimated $8.16M sold.

Based on aggregated 13F filings for Q2 2019.